Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.39 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28852482 | 0.79 | SRC (0.42) | SRCALDH1A1 | |
| SCHEMBL3033594 | 0.74 | EGFR (0.34) | ALDH1A1 | |
| SCHEMBL28742021 | 0.73 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL19136489 | 0.73 | ALDH1A1 (0.46) | KDM4ETDP1ALDH1A1HPGDMEN1 | |
| SCHEMBL2800490 | 0.73 | TRPV4 (0.52) | ALDH1A1 | |
| SCHEMBL31432810 | 0.72 | ALDH1A1 (0.52) | KDM4ETDP1ALDH1A1LMNAHPGD | |
| SCHEMBL1795902 | 0.72 | TSHR (0.43) | KDM4ETDP1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL1344362 | 0.72 | KDM4E (0.46) | KDM4ERECQLUPP1TDP1ALDH1A1 | |
| SCHEMBL8851985 | 0.72 | KDM4E (0.46) | KDM4ERECQLUPP1TDP1ALDH1A1 | |
| SCHEMBL814444 | 0.72 | SRC (0.48) | SRCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3600294-B1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-114574988-B | Preparation method of flame-retardant polyamide 6 fiber based on phosphorus-nitrogen synergistic flame retardant | 东华大学 | 2024-01-30 | — | — | CN | disclosed |
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2023-12-19 | — | — | US | disclosed |
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| CN-114574988-A | Preparation method of flame-retardant polyamide 6 fiber based on phosphorus-nitrogen synergistic flame retardant | 东华大学 | 2022-06-03 | — | — | CN | disclosed |
| US-20220073514-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-10 | — | — | US | disclosed |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC | 2020-07-30 | — | — | US | disclosed |
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| WO-2019005241-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2017-11-16 | — | — | US | disclosed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | disclosed |
| WO-2013186612-A1 | THE USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BET (BROMODOMAIN AND EXTRA TERMINAL DOMAIN) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-12-19 | — | — | WO | disclosed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-03-08 | — | — | US | disclosed |
| EP-2421533-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123975-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059002-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4E 3020/4885RECQL 3294/4885UPP1 4228/4885 |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | KDM4E 1460/4885RECQL 4558/4885UPP1 3025/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | KDM4E 342/4885RECQL 1820/4885UPP1 2890/4885 |
| US-20220073514-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | KDM4E 1460/4885RECQL 4558/4885UPP1 3025/4885 |
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | KDM4E 1460/4885RECQL 4558/4885UPP1 3025/4885 |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | KDM4E 1460/4885RECQL 4558/4885UPP1 3025/4885 |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4E 3020/4885RECQL 3294/4885UPP1 4228/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4E 3020/4885RECQL 3294/4885UPP1 4228/4885 |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | KDM4E 3020/4885RECQL 3294/4885UPP1 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.